Recent progress in genetic variants associated with cancer and their implications in diagnostics development

Expert Review of Molecular Diagnostics

Volumn 10, Issue 6, 2010, Pages 699-703

  Cho, William Cs ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CYCLIN DEPENDENT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1BETA; INTERLEUKIN 16; MICRORNA; MOLECULAR MARKER; NOTCH2 RECEPTOR;

BASAL CELL CARCINOMA; BREAST CANCER; CANCER DIAGNOSIS; COLORECTAL CANCER; COPY NUMBER VARIATION; EARLY DIAGNOSIS; EDITORIAL; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLIOMA; HUMAN; LEUKEMIA; LUNG CANCER; MELANOMA; NASOPHARYNX CARCINOMA; NEUROBLASTOMA; PANCREAS CANCER; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER;

GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MICRORNAS; NEOPLASMS;

EID: 77956790240     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.64     Document Type: Editorial

References (60)

1. Dimas AS, Dermitzakis ET. Genetic variation of regulatory systems. Curr. Opin. Genet. Dev. 19(6), 586-590 (2009).
2. Ku CS, Chia KS. The success of the genome-wide association approach: a brief story of a long struggle. Eur. J. Hum. Genet. 16(5), 554-564 (2008).
3. Stankiewicz P, Lupski JR. Structural variation in the human genome and its role in disease. Annu. Rev. Med. 61, 437-455 (2010).
4. Wain LV, Armour JA, Tobin MD. Genomic copy number variation, human health, and disease. Lancet 374(9686), 340-350 (2009).
5. Zhang F, Gu W, Hurles ME et al. Copy number variation in human health, disease, and evolution. Annu. Rev. Genomics Hum. Genet. 10, 451-481 (2009).
6. Shlien A, Tabori U, Marshall CR et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc. Natl Acad. Sci. USA 105(32), 11264-11269 (2008).
7. Dear PH. Copy-number variation: the end of the human genome? Trends Biotechnol. 27(8), 448-454 (2009).
8. Wu X, Hildebrandt MA, Chang DW. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev. 28(3-4), 269-280 (2009).
9. Ioannidis JP, Castaldi P, Evangelou E. A compendium of genome-wide associations for cancer: critical synopsis and reappraisal. J. Natl Cancer Inst. 102(12), 846-858 (2010).
10. Yeager M, Orr N, Hayes RB et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39(5), 645-649 (2007).
11. Gudmundsson J, Sulem P, Manolescu A et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39(5), 631-637 (2007).
12. Thomas G, Jacobs KB, Year M et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40(3), 310-315 (2008).
13. Gudmundsson J, Sulem P, Rafnar T et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet. 40(3), 281-283 (2008). (Pubitemid 351311771)
14. Gudmundsson J, Sulem P, Gudbjartsson DF et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet. 41(10), 1122-1126 (2009).
15. Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39(7), 870-874 (2007).
16. Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39(7), 865-869 (2007).
17. Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 40(6), 703-706 (2008).
18. Zheng W, Long J, Gao YT et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat. Genet. 41(3), 324-328 (2009).
19. Thomas G, Jacobs KB, Kraft P et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet. 41(5), 579-584 (2009).
20. Ahmed S, Thomas G, Ghoussaini M et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet. 41(5), 585-590 (2009).
21. Turnbull C, Ahmed S, Morrison J et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat. Genet. 42(6), 504-507 (2010).
22. Tomlinson I, Webb E, Carvajal-Carmona L et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat. Genet. 39(8), 984-988 (2007).
23. Tomlinson I, Webb E, Carvajal-Carmona L et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat. Genet. 40(5), 623-630 (2008). (Pubitemid 351601204)
24. Tenesa A, Farrington SM, Prendergast JG et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat. Genet. 40(5), 631-637 (2008).
25. Sakamoto H, Yoshimura K, Saeki N et al.; Study Group of Millennium Genome Project for Cancer. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 40(6), 730-740 (2008).
26. Papaemmanuil E, Hosking FJ, Vijayakrishnan J et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat. Genet. 41(9), 1006-1010 (2009).
27. Di Bernardo MC, Crowther-Swanepoel D, Broderick P et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40(10), 1204-1210 (2008).
28. Crowther-Swanepoel D, Broderick P, Di Bernardo MC et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat. Genet. 42(2), 132-136 (2010).
29. Brown KM, Macgregor S, Montgomery GW et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat. Genet. 40(7), 838-840 (2008).
30. Bishop DT, Demenais F, Iles MM et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat. Genet. 41(8), 920-925 (2009).
31. Stacey SN, Gudbjartsson DF, Sulem P et al. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat. Genet. 40(11), 1313-1318 (2008).
32. Stacey SN, Sulem P, Masson G et al. New common variants affecting susceptibility to basal cell carcinoma. Nat. Genet. 41(8), 909-914 (2009).
33. Amos CI, Wu X, Broderick P et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40(5), 616-622 (2008).
34. McKay JD, Hung RJ, Gaborieau V et al. Lung cancer susceptibility locus at 5p15.33. Nat. Genet. 40(12), 1404-1406 (2008).
35. Wang Y, Broderick P, Webb E et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat. Genet. 40(12), 1407-1409 (2008).
36. Sholl LM, Yeap BY, Iafrate AJ et al. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res. 69(21), 8341-8348 (2009).
37. Soh J, Toyooka S, Ichihara S et al. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J. Thorac. Oncol. 3(4), 340-347 (2008).
38. Tang X, Varella-Garcia M, Xavier AC et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev. Res. (Phila. PA) 1(3), 192-200 (2008).
39. Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res. 68(7), 2106-2111 (2008).
40. Capasso M, Devoto M, Hou C et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat. Genet. 41(6), 718-723 (2009).
41. Wrensch M, Jenkins RB, Chang JS et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat. Genet. 41(8), 905-908 (2009).
42. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat. Genet. 41(9), 986-990 (2009).
43. Petersen GM, Amundadottir L, Fuchs CS et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat. Genet. 42(3), 224-228 (2010).
44. Bei JX, Li Y, Jia WH et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat. Genet. 42(7), 599-603 (2010).
45. Cho WC. MicroRNAs in cancer -from research to therapy. Biochim. Biophys. Acta 1805(2), 209-217 (2010).
46. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol. 42(8), 1273-1281 (2010).
47. Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev. Mol. Diagn. 10(3), 297-308 (2010).
48. Sethupathy P, Collins FS. MicroRNA target site polymorphisms and human disease. Trends Genet. 24(10), 489-497 (2008).
49. Cho WC. Role of miRNAs in lung cancer. Expert Rev. Mol. Diagn. 9(8), 773-776 (2009).
50. Chin LJ, Ratner E, Leng S et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res. 68(20), 8535-8540 (2008).
51. Tchatchou S, Jung A, Hemminki K et al. A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis 30(1), 59-64 (2009).
52. Christensen BC, Whiting MA, Ouellet LG et al. Mature miRNA sequence polymorphism in MIR196A2 is associated with risk and prognosis of head and neck cancer. Clin. Cancer Res. 16(14), 3713-3720 (2010).
53. Manolio TA, Collins FS, Cox NJ et al. Finding the missing heritability of complex diseases. Nature 461(7265), 747-753 (2009).
54. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat. Rev. Genet. 11(6), 415-425 (2010).
55. Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet. 24(3), 133-141 (2008).
56. Galvan A, Ioannidis JP, Dragani TA. Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet. 26(3), 132-141 (2010).
57. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat. Rev. Cancer 10(5), 353-361 (2010).
58. Cho WC. Omics approaches in cancer research. In: An Omics Perspective on Cancer Research. Cho WC (Ed.). Springer, Berlin, Germany 1-9 (2010).
59. Cho WC. Conquering cancer through discovery research. IUBMB Life 62(9), 646-650 (2010).
60. 1000 Genomes: a deep catalog of human genetic variation http://1000genomes.org/page.php (Accessed 21 August 2010)